ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1719

What Do Patients Put up with for the Benefit They Get From Methotrexate?

Sandra M. Robinson1, Peta S. Heslop1 and David Walker2, 1R&D, North Tyneside General Hospital, North Shields, United Kingdom, 2Dept of Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: methotrexate (MTX)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Care of Patients With Rheumatoid Arthritis

Session Type: Abstract Submissions (ARHP)

Background/Purpose:

As with all effective drugs, Methotrexate (MTX) comes with a range of side effects. Some such as pneumonitis are severe enough to require the drug to be stopped. Others such as nausea are more about what a patient will tolerate. We were aware that many patients were tolerating side effects in order to take MTX. If the benefits outweigh the problem, then the medical advice would be to continue. This also applies to patients taking methotrexate in combination with TNFis where there is considerable advantage from taking the combination. For this reason there was little interest in exploring methotrexate “tolerability”. However, there is now good evidence that Tocilizumab works as well alone as in combination with Methotrexate. This offers the possibility that some patients struggling with methotrexate may be better off on Tocilizumab monotherapy rather than a TNFi and their MTX. We were interested to quantify the tolerability problems of patients continuing on Methotrexate therapy.

Methods:

100 consecutive patients seen in outpatient clinics, who were taking a stable dose of MTX and planning to continue, were surveyed. A study sheet was completed seeking information on the effectiveness of the MTX, their concordance with treatment and any side effects they were getting. They were specifically asked about: nausea; fatigue; mouth ulcers and hair loss and asked to rate them on a VAS.

68 were female and 32 were male with an average age of 59 (24 – 84 yrs). 89 were on oral and 11 on subcutaneous injections. 75 patients were suffering from RA, 18 patients from psoriatic arthritis with 7 patients having other indications.

Results:

Efficacy averaged 6.5 being similar in men and women (6.7 & 6.4). 56% complained of at least one side effect. The side effects and the judged severity are shown in the table. VAS scores for severity averaged in the range 3.5 to 5. Sex differences were apparent. Men were less likely to complain of problems, in particular hair loss and nausea. Whether this relates to tolerance or intolerance is not clear.  Only 10% “forgot” to take their MTX for an average of 2 weeks in a year. 5 chose not to take an average of 2.6 doses in a year. These patients had higher intensity of side effects (6-9.5)

 

 

Nausea*

 

 

Mouth

Ulcers

 

Hair

Loss**

 

 

Fatigue

 

Other

S/Es

 

Any

Side Effect

 

WOMEN

n=68

 

 

4.3 (±2.5)

n=22 (32%)

 

4.3 (±2.9)

n=18 (26%)

 

3.5 (±2.2)

n=13 (19%)

 

5.0 (±1.9)

n=17 (25%)

 

5.5 (±3.4)

n=6

 

 

4.6

n=43 (63%)

 

 

MEN

n=32

 

3.4 (±2.1)

n=4 (13%)

 

2.7 (±2.0)

n=9 (28%)

 

0.0

n=0 (0%)

 

4.3 (±0.8)

n=3 (9%)

 

2.8 (±0.6)

n=3

 

 

2.8

n=13 (41%)

 

 

TOTALS

 

n=26

 

n=27

 

 

n=13

 

n=20

 

n=9

 

n=56

 

Chi Test x2

*p<0.05 **p<0.01

Conclusion:

 Patients are putting up with a lot of side effects, which are outweighed by the benefits of MTX for them. When a biologic is necessary to control their disease, some patients may be attracted by one that does not require combination with MTX.


Disclosure:

S. M. Robinson,
None;

P. S. Heslop,
None;

D. Walker,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/what-do-patients-put-up-with-for-the-benefit-they-get-from-methotrexate/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology